- Published at
- by manilatimes.net
mixed
mixed
News for Vericel Corporation (VCEL)
- Published at
- by manilatimes.net
mixedmixed- Published at
- by seekingalpha.com
positivepositiveVericel Stock: Scalable Growth With Strong Margins (NASDAQ:VCEL)
Vericel's FDA-approved regenerative medicine products and robust pipeline signal strong growth potential, with zero debt and rising revenue. See more here.- Published at
- by gurufocus.com
mixedmixedVericel to Present at Multiple Upcoming Investor Conferences
CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (VCEL), a leader in advanced therapies for the sports medicine and severe burn care m- Published at
- by gurufocus.com
positivepositiveQ4 2024 Vericel Corp Earnings Call Transcript
Feb 27, 2025 / 01:30PM GMTOperator Good day and thank you for standing by. Welcome to the Vericel Corporation 4th quarter 2024 earnings call. At this time, all- Published at
- by seekingalpha.com
positivepositiveVericel Corporation (VCEL) Q4 2024 Earnings Conference Call Transcript
Vericel Corporation (NASDAQ:VCEL) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ETCompany ParticipantsNick Colangelo - CEOJoe Mara - CFOEric...- Published at
- by seekingalpha.com
neutralneutralVericel Corporation 2024 Q4 - Results - Earnings Call Presentation (NASDAQ:VCEL)
The following slide deck was published by Vericel Corporation in conjunction with their 2024 Q4 earnings call.- Published at
- by zacks.com
positivepositiveVericel Corporation (VCEL) Tops Q4 Earnings Estimates
Vericel (VCEL) delivered earnings and revenue surprises of 26.67% and 0.10%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by gurufocus.com
neutralneutralVericel Reports Fourth Quarter and Full-Year 2024 Financial Results
Full-Year Total Revenue Growth of 20% to $237.2 Million, with MACI Revenue Growth of 20% and Burn Care Revenue Growth of 22% Full-Year Adjusted EBITDA Growth o- Published at
- by seekingalpha.com
neutralneutralVericel Q4 2024 Earnings Preview (NASDAQ:VCEL)
Vericel (VCEL) reports Q4 earnings on Feb 27th. Analysts forecast $0.34 EPS & $76.47M revenue.- Published at
- by zacks.com
positivepositiveVericel (VCEL) Is a Great Choice for 'Trend' Investors, Here's Why
Vericel (VCEL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.- Published at
- by finance.yahoo.com
mixedmixedStock Market Today: Dow Jones Soars 700 Points As Inflation Cools; Nvidia Rebounds As Quantum Stocks Fly (Live Coverage)
The Dow Jones Industrial Average soared 700 points after inflation cooled in December. Nvidia rebounded in the stock market today.- Published at
- by investors.com
mixedmixedStock Market Today: Dow Jones Pares Gains; Nvidia Rebounds As Several Stocks Top Buy Points (Live Coverage)
The Dow Jones Industrial Average soared 600 points after inflation cooled in December. Nvidia rebounded in the stock market today.- Published at
- by benzinga.com
mixedmixedApplied Digital, Vericel, Calavo Growers And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Applied Digital (NASDAQ:APLD), Alvotech (NASDAQ:ALVO)
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday. Shares of Applied Digital Corporation APLD fell sha...- Published at
- by gurufocus.com
mixedmixedVericel Announces Preliminary 2024 Financial Results, 2025 Financial Guidance and Increased Mid-Term Profitability Targets
Full-Year 2024 Total Revenue Growth of 20% and Adjusted EBITDA Growth of Approximately 55% MACI Full-Year 2024 Revenue Growth of 20%, with Fourth Quarter Reven- Published at
- by seekingalpha.com
neutralneutralVericel expects 2024 net revenue in range of $237 to $237.5 million (NASDAQ:VCEL)
Vericel Corporation (VCEL) expects strong revenue growth in 2024 and 2025, with gross margin and EBITDA margin also showing positive trends.- Published at
- by manilatimes.net
mixedmixed- Published at
- by investing.com
neutralneutralVericel's preliminary Q4 revenue falls short of analyst expectations; shares fall 11% post market By Investing.com
Vericel's preliminary Q4 revenue falls short of analyst expectations; shares fall 11% post market- Published at
- by manilatimes.net
mixedmixed- Published at
- by seekingalpha.com
positivepositiveVericel Corporation: Hard To Justify Current Valuation (NASDAQ:VCEL)
Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Click for more on VCEL.